Prostate cancer is the most common cancer diagnosed in men. Chemotherapy, androgen ablation, and androgen antagonist treatments have proven to have significant effects in the early stages of prostate cancer, whereas advanced prostate cancer is resilient to such treatments. The androgen receptor (AR), a ligand-dependent transcription factor, is the major drug target of prostate cancer therapy. Transition to the androgen-independent stage involves the activation of signaling pathways, AR gene mutations, and other mechanisms. Higher basidiomycetes mushrooms have been used since ancient times in folk medicine to treat a diversity of diseases, including cancer. The present study evaluates the antiandrogenic activity of different Coprinus comatus strains in their ability to interfere with AR function. The authors found that the most active extract was C comatus strain 734 extracted with hexane (CC734-H). This extract was able to (1) inhibit AR-mediated reporter activity, (2) inhibit the proliferation and viability of the LNCaP cell line, and (3) inhibit the colony formation of the LNCaP cell line, in comparison to the DU-145, PC-3, and MDA-Kb2 cells. In addition, CC734-H was able to reduce AR levels and prostate-specific antigen gene expression in the LNCaP-treated cell line. This study illustrates the potential of the C comatus mushroom as a natural antiandrogenic modulator that could serve in the treatment of prostatic diseases.
Introduction
Prostate cancer is the most frequently diagnosed cancer in men, with more than 192 000 new cases projected to occur in 2009 in the United States. Nearly three quarters of these cases will be diagnosed in economically developed countries. Prostate cancer is the second leading cause of cancer death in men (American Cancer Society, 2009), and it is estimated that about 27 000 individuals will die from the disease in 2009 in the United States. The development of prostate cancer is a multistep process, including a series of morphologically distinct lesions initiated by genetic and epigenetic changes. Established risk factors include old age, race (black), and family history of prostate cancer. Other potential risk factors, such as environment and diet, have also been suggested. 1 Androgens play an important role in the control of normal prostate glandular growth, in the promotion of benign prostatic hyperplasia (BPH), and in prostate cancer. 2 Testosterone is the most abundant androgen in the sera, but in the prostatic epithelia, it is converted into a more potent androgen, dihydrotestosterone (DHT), by the resident enzyme, 5a-reductase. 3 Androgen exerts its biological effects through the androgen receptor (AR), a member of the nuclear receptor superfamily that acts as a liganddependent transcription factor. [4] [5] [6] Prior to ligand binding, the AR is held inactive through its association with heat shock proteins (HSPs) and is thus precluded from DNA binding. Administration and binding of androgens release inhibitory HSPs, and the receptor is rapidly translocated to the nucleus where it binds DNA as a homodimer on androgen-responsive elements within the regulatory regions of target genes. 6, 7 The most common therapeutic option for prostate cancer is androgen ablation, via surgical or medical castration, and chemotherapy because early tumors are androgen dependent. 8 Another option is treatment with antiandrogens (androgen antagonists), which can block the AR-mediated gene transactivation. Therefore, in current treatments, steroidal antiandrogens are applied. 9 However, advanced prostate cancer is resilient to most treatments. Despite the early efficacy of androgen ablation, prostate tumors eventually relapse into a hormonerefractory (androgen-independent) stage, having devastating results on morbidity and mortality rates. 10, 11 The transition to androgen independence is followed by metastasis, with more than 80% of all tumors metastasizing to the bone. 12 Potential mechanisms for transition to the androgen-independent stage include AR amplification and AR gene mutations. Mutations in AR altered ligand specificity and thus enabled receptor activation by other steroids and androgens. [13] [14] [15] In addition, alternative pathways are activated that involve the loss of PTEN, activation of PI3K/Akt/NF-kB pathways, and upregulation of other antiapoptotic genes, such as Bcl2, Bcl-xL, and survivin. [16] [17] [18] [19] Natural products and their derivatives have historically been invaluable sources of therapeutic agents and possess an exclusive potential as immunomodulators and dietary supplements. 20 In the case of anticancer agents, natural products, including mushrooms, have made significant contributions as direct treatments or as templates for synthetic modification. 21, 22 Fungi from the Basidiomycota phylum have been of great interest because of the high number of biologically active compounds isolated from them exhibiting anticancer activity. [23] [24] [25] One member of the phylum is Coprinus comatus, a member of the Coprinus genus.
The present study was undertaken to screen organic extracts from different C comatus strains to find a potential strain and, later on, active moieties that interfere with AR activity. Previously, Zaidman et al 26 demonstrated that the ethanol extract of C comatus strain 97 was able to interfere with AR activity. In this study, we screened a variety of C comatus strains and monitored their antiandrogenic activity. We were successful in identifying C comatus extracts with enhanced potency that interfere with AR function. Our data illustrated that the hexane (H) extract prepared from C comatus strain 734 was the most active one and was able to decrease AR and glucocorticoid receptor (GR)-transcription activity in DHT and DEX-induced MDA-kb2 breast cancer cells respectively, cause growth inhibition of androgendependent LNCaP cells in a selective manner, and inhibit the colony formation ability of LNCaP cells. In addition, this extract caused a decrease in AR and prostate-specific antigen (PSA) gene expression levels in DHT-induced LNCaP cells.
These findings support our hypothesis that substances from the C comatus mushroom have potential use in prostate cancer therapy.
Materials and Methods

Fungi Growth Conditions
A total of 7 strains of C comatus from the higher basidiomycetes culture collection at the Institute of Evolution, University of Haifa, were selected for this study. The selected C comatus strains were CC96, CC97, CC252, CC542, CC784, CC263, and CC734.
Preinocula for cultures were prepared as previously described 26 by transferring 10 discs of 5 mm diameter from the different C comatus strains to flasks containing 100 mL of YE medium (g/L; yeast extract 1, peptone 1, glucose 20, KH 2 
Fungi Extraction
Mycelia were separated from the culture broth by paper filtering, washed to remove the culture broth, and dried at 37°C. The dry mycelia were ground to a fine powder and extracted 3 times with ethyl acetate (EA), H, chloroform (C), or ethanol (E) for 2 hours each time in a rotary shaker at 160 rpm at room temperature. The culture broth was extracted 3 times with EA under the same conditions. Solvents were removed under reduced pressure. The resulting stock solutions were prepared in dimethylsulfoxide (DMSO) and stored at -70°C.
Cancer Cell Lines and Cell Culture
Human MDA-kb2 breast carcinoma, DU-145, and PC-3 ARindependent prostate cancer cell lines (ATCC, Rockville, MD) were grown in RPMI 1640 containing 2 mM l-glutamine, 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 mg/mL streptomycin. LNCaP androgen-dependent prostate cancer cell lines were grown in RPMI 1640 containing 2 mM l-glutamine, 10% FBS, 1% sodium bicarbonate, 1% Hepes buffer, 100 IU/mL penicillin, and 100 mg/mL streptomycin. All cell lines were grown at 37°C in a humidified atmosphere with 5% CO 2 . Cells in the different assays were induced by the AR ligand, DHT, or the GR ligand, dexamethasone (DEX).
Luciferase Reporter Assay
MDA-kb2 cells were plated (5 × 10 5 cells/well) in 12-well plates containing 3 mL of phenol red-free medium supplemented with 10% charcoal-stripped FBS. After 48 hours, fungal extracts at a final concentration of 50 mg/mL in 1% DMSO were added, in addition to 5 nM DHT or 10 nM DEX. DHT-and DEX-treated samples also included solvent (DMSO) at a final concentration of 1%. Then, 24 hours later, treated cells were collected, washed twice with phosphate-buffered saline (PBS) and lysed with 50 mL lysis buffer (Promega, Madison, WI). Following incubation for 30 minutes at 4°C, samples were centrifuged at 10 000g for 10 minutes, and the supernatant was assayed for luciferase activity. Luciferase activity was determined using a microtiter plate luminometer (Perkin Elmar, MA) and quantified as relative light units. These units were normalized against the total cell lysate protein concentration, as determined by the Bio-Rad DC protein assay, according to manufacturer's instructions (Bio-Rad, Hercules, CA).
Trypan Blue Exclusion Assay
LNCaP, PC-3, or MDA-kb2 cell lines were plated (4 × 10 5 cells/well) in 6-well plates, with each well containing 3 mL medium. After 24 hours, various fungal extracts at concentrations of 0, 5, 25, and 125 mg/mL were added. Solvent-treated samples were incubated with 1% DMSO; 48 hours later, the cells were collected, stained with 0.4% trypan blue solution (1:1), and counted using a hemacytometer to determine IC 50 values, which were calculated for each organic extract.
Colony-Forming Assay
A colony-forming assay was performed as previously described. 27 Briefly, cells (1 × 10 4 ) in 1 mL RPMI/10% FBS medium were diluted in 1 mL of 0.6% agar to give a final agar concentration of 0.3% agar. The cell-agar mixture was poured on top of a hardened agar base in wells of 12-well plates and allowed to solidify. Once the top layer solidified, 1 mL of medium containing different treatments was placed on top to keep the agar moist. The cells were grown at 37°C in a 5% CO 2 humidified atmosphere until colonies were visible (2-3 weeks). The plates were stained for 4 hours with 5 mg/mL 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and the dye was extracted with 1 mL solubilization buffer (20% sodium dodecyl sulfate [SDS], 50% N,N-dimethyl-formamide, 25 mM HCL) for 24 hours. The optical density was measured at 570 nm wavelength with a reference wavelength of 630 nm.
Preparation of Nuclear Extracts From LNCaP Cells
Nuclear extracts from LNCaP cells were prepared according to manufacturer's instructions (Sigma-Aldrich, Rehovot, Israel). Briefly, the cells were collected, washed twice with 1× PBS, pelleted by centrifugation at 900g for 3 minutes at 4°C, resuspended in a 5 × packed cell volume of the hypotonic lysis buffer [10 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl containing 1mM Dithiothreitol (DTT) supplemented with 1% of a protease inhibitor cocktail], and incubated for 15 minutes on ice, allowing the cells to swell. To the swollen cells in hypotonic lysis buffer, 10% IGEPAL CA-630 solution was added to a final concentration of 0.6%. Cells were homogenized by vortexing vigorously for 10 s and centrifuging for 30 s at 10 000g. The supernatant (the cytoplasmic fraction) was transferred to fresh tubes and stored at -70°C (after protein concentration determination). The resulting pellet containing "crude" nuclei was resuspended in 3 packed cell volumes of extraction buffer (20 mM HEPES pH 7.9, 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, 25% glycerol containing 1 mM DTT, and 1% protease inhibitor cocktail), agitated at medium speed in a vortex mixer for 30 minutes, and centrifuged at 20 000 g for 5 minutes. The supernatant (the nuclear fraction) was aliquoted and stored at -70°C. All steps were performed at 4°C, and the precooled buffers were used to prevent proteolytic degradation of the proteins.
Detection of AR by Immunoblotting Assay
Treated cells were washed twice with PBS and lysed with 100 mL of lysis buffer (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA, 1 mM Ethylene glycol tetraacetic acid (EGTA), 1 mM NaF, 20 mM Na 4 P 2 O 7 , 2 mM Na 3 VO 4 , 1% Triton X-100, 10% glycerol, 1 mM Phenylmethanesulfonylfluoride (PMSF), 0.1% SDS, and 0.5% sodium deoxycholate, supplemented with a protease and phosphatase inhibitor cocktail). Cell debris were removed from cell lysates by centrifugation at 150g for 10 minutes at 4°C. Protein concentrations were determined using Bio-Rad DC protein assay according to manufacturer's instructions (Bio-Rad Laboratories, Hercules, CA). Equal amounts of protein (40 mg) were separated on 10% SDS-PAGE gels. The PAGEseparated proteins were transferred to a nitrocellulose membrane and incubated overnight at 4°C with AR polyclonal primary antibody (Santa Cruz Biotechnology, CA, USA) or a-tubulin antibody (Santa Cruz Biotechnology, CA, USA). Membranes were washed, incubated with an Horseradish peroxidase (HRP)-conjugated secondary antibody, developed using Enhanced chemical luminiscence (ECL) detection reagents (Bio-Rad, Hercules, CA), and visualized on Kodak BIOMAX MR Films (Sigma-Aldrich, Rehovot, Israel).
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Total RNA from cell samples was extracted using TRI Reagent ® according to manufacturer's instructions (Sigma, Rehovot, Israel). Then, 1 mg of the total RNA was reverse transcribed into cDNA using the Avian myeloblastosis virus (AMV) RT kit (Promega, Madison, WI) and oligo (dT17) primer. Semiquantitative RT-PCR was carried out under the following conditions: 2.5 mL of cDNA, 1 U Taq DNA polymerase (Bioline, MA), 2.5 mL 10 × PCR buffer, 1.5 mL 50 mM MgCl 2 , 1 mL 25 mM dNTPs, and 7.5 pmol of each specific upstream and downstream primer. The individual primer sequences were as follows: AR (forward), 5'-CCTGGCTTCCGCAACTTA-CAC-3', AR (reverse), 5'-GGACTTGTGCATGCGGTACTC-3' PSA (forward), 5'-CAACTCCCTATTGTAGTAAAC-3' PSA (reverse), 5'-GCTCACAGCCTTCTCTAG-3' "Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (forward), 5'-AGT-CAACGGATTTGGTCGTA-3' "GAPDH (reverse), 5'-AAATGAGCCCCAGCCTTCT-3' GAPDH primers were used as an internal standard. The number of cycles required to obtain semiquantitative amplifications for each target gene was determined empirically. PCR conditions were as follows: initial 2 minutes at 94°C; followed by the empirically determined number of cycles, 30 s at 94°C, annealing at 55°C for 30 s, and extension at 72°C for 2.5 minutes. The final extension period was at 72°C for 15 minutes.
Densitometric Analysis
Densitometric quantitative analyses of the protein bands detected by Western blot and RT-PCR were carried out using the Tina software and are presented as the volumes of bands of interest divided by the volumes of bands of the house-keeping protein or the gene used, a-tubulin, or GAPDH, respectively.
Results
Zaidman et al 26 demonstrated that organic extracts of Ganoderma lucidum and C comatus strain 97 inhibited AR function. 26 To further evaluate the antiandrogenic potential of the C comatus mushroom, 7 C comatus strains (CC96, CC97, CC252, CC542, CC784, CC263, and CC734) were investigated.
C comatus Extracts Inhibit AR-Mediated Reporter Activity
The 7 C comatus strains were used to prepare 35 extracts using a variety of solvents, such as EA, H, C, and E. In addition, extracts were prepared from mycelium. Dry extracts were used to prepare stock solution in 100% DMSO. Diluted extracts were added to cancer cells with the appropriate concentrations that included DMSO at 1%. Solvent-treated samples were incubated with 1% DMSO. Initially, we monitored the ability of C comatus organic extracts to influence AR-mediated reporter activity using MDA-kb2 cells. MDA-kb2 cells are MDA-MB-453 breast cancer cells stably transfected with a mouse mammary tumor virus (MMTV) luciferase-neo reporter gene construct, 28, 29 which is responsive to AR and GR activation. The presence of DHT and DEX activates AR and GR, respectively, leading to the binding of the appropriate receptor to the MMTV promoter and initiating transcription of the luciferase gene. MDA-kb2 cells were treated with the appropriate C comatus extracts in the presence of either 5 nM DHT or 10 nM DEX, and reporter activity was monitored. The data obtained, summarized in Figure 1 , demonstrated that both ligands (DHT and DEX) were effective in inducing reporter activity by about 5-fold ( Figure 1A ). The presence of 5 µM flutamide, an AR inhibitor, partially inhibited DHT-induced reporter activity but not DEX-induced reporter activity, providing evidence of flutamide selectivity for AR ( Figure 1A) . The GR inhibitor, RU-486 (1 mM), caused a significant reduction in DEX-induced reporter activity and had a minimal effect on DHT-induced reporter activity, demonstrating RU-486 specificity for GR ( Figure 1A) .
The presence of C comatus biomass (B) extracts CC96-EA, CC252-EA, CC252-H, CC542-C, CC734-EA, CC734-H, and CC263-E inhibited DHT-and DEX-induced reporter activity at a concentration of 50 mg/mL with similar potency (Figure 1 , Table 1 ). Extracts from the growth medium (M), CC96-M, CC97-M, CC252-M, CC542-M, CC784-M, CC263-M, and CC734-M failed to inhibit either DHT-or DEX-induced reporter activity, implying that the growth medium extracts are void of the desired activity. CC97-E was previously investigated by Zaidman et al 26 and was reported to inhibit AR transcriptional activity by 47% at a concentration of 50 mg/mL. All extracts presented in Table 1 , except CC542-C, were capable of interfering with both DHT-and DEX-induced reporter activity by more than 60% ( Figure 1 , Table 1 ). The C extract prepared from C comatus strain CC542 showed selectivity toward the DHT-induced as opposed to the DEX-induced reporter activity, leading to AR inhibition but not to GR transcriptional activity. These results indicated that CC542-C works in a selective manner toward AR and in a different way from the other extracts (Figure 1, Table1 ).
Growth Inhibition of LNCaP Cell Line by C comatus Extracts
The various organic extracts of C comatus biomass were tested for their ability to affect proliferation of the androgen-dependent prostate cancer cell line, LNCaP; the AR-independent prostate cancer cell line, PC-3; and the breast cancer cell line expressing AR, MDA-Kb2. Trypan blue dye exclusion membrane integrity assay was used to assess cell viability and to estimate IC 50 values for the selected extracts. Data shown in Table 2 illustrate that C comatus extracts CC542-C, CC734-H, and CC263-E inhibited the proliferation of LNCaP cells with IC 50 values below 50 mg/mL and were less effective in inhibiting the proliferation of the PC-3 and MDA-Kb2 cell lines, denoting their selectivity toward the androgen-dependent LNCaP cells. These extracts apparently interfere with AR activity, causing a decrease in cell viability of the androgen-dependent cells. The CC734-EA, CC96-EA, and CC252-H extracts inhibited the proliferation of LNCaP and PC3 cell lines with equal potency, with no apparent selectivity between LNCaP and PC-3 cells. The above-mentioned extracts were less effective in inhibiting the proliferation of MDA-Kb2 cells, implying that they were more specific for prostate cancer cell lines. In contrast, the CC252-EA extract inhibited proliferation of all cell lines tested in this study, with no selectivity, with an IC 50 value of about 100 mg/mL
C comatus Extracts Reduce the Colony-Forming Ability of Prostate Cancer Cell Lines
As anchorage-independent growth is an approximation of tumorigenesis of cancer cells, we tested the ability of C comatus extracts to affect the colony formation of LNCaP, PC-3, DU-145, and MDA-Kb2 cell lines. As shown in Figure 2 , 50 mg/mL CC734-H was able to reduce the colony-forming ability of LNCaP cells by 60%, compared with 15% and 11% in PC-3 and DU-145 cell lines, respectively (Figure 2 ). CC542-C at the same concentration reduced colony formation in LNCaP cells by 55%, compared with 13% in PC-3 and 26% in DU-145 cell lines. CC263-E caused a 71% reduction in the ability of the LNCaP cell line to form colonies, in comparison to 18% and 28% reduction in PC-3 and DU-145 cell lines, respectively. All extracts at the indicated concentration marginally affected MDA-Kb2 cell colony formation and caused a reduction of ~10% (Figure 2A) . These results provide evidence that C comatus extracts preferably influence the colony-forming ability of the androgen-dependent prostate cancer cell line, with a minimal effect on androgen-independent prostate or nonprostate cancer cell lines.
Effect of C comatus Extracts on AR Protein Translocation
Regulation of AR function is mediated, in part, by its localization to cytoplasm or to the nucleus. To elucidate the mechanism of action of our C comatus extracts, we monitored their effect on AR translocation from the cytoplasm to the nucleus. Flutamide, which acts as a DHT competitor, binds the AR and prevents it from being translocated to the nucleus. LNCaP cell lines were treated with C comatus extracts for 2 hours in the presence and absence of DHT. Subsequently, cytoplasmic and nuclear protein fractions were extracted and subjected to immune blotting using anti-AR antibody. The results in Figure 3 showed that in solventtreated cells, the AR protein levels in the cytoplasm and in the nucleus are similar. Following the addition of DHT, the AR was located mostly in the nucleus. The presence of 5 mM flutamide moderately prevented AR nuclear translocation. Treatment with the indicated concentrations of C comatus CC734-H, CC252-EA, CC542-C, and CC263-E extracts did not inhibit AR from entering the nucleus, indicating that the inhibition of AR translocation is not the mechanism of action of the C comatus extracts. The same filters were reprobed with PARP, a nuclear protein, 30 and HSP-70, found at both cytoplasmic proteins and at the nucleus 31 to confirm the lack of cytoplasmic proteins contaminating the nuclear fractions. 
C comatus Extracts Inhibit AR Transcriptional Activity and Reduce AR Protein Levels
The inhibition of AR-mediated reporter activity, caused by the presence of C comatus extracts, as shown in Figure 4A , was verified once again in the MDA-Kb2 cells ( Figure 4A ). To examine whether the reduction of AR activity was caused by a decrease in AR protein level, Western blot analysis was carried out. MDA-Kb2 cells were treated with C comatus CC96-EA, CC252-EA, CC542-C, CC734-H, and CC263-E extracts for 24 hours, and the levels of DHT-induced reporter activity and AR protein levels were monitored. According to the results summarized in Figure 4A , all tested extracts inhibited DHTinduced AR transcriptional activity in concentrations of 25 and 50 mg/mL. Furthermore, 10 mM SKI-606, a dual src and Abl kinase inhibitor, 32 also caused a significant reduction in AR transcriptional activity.
Western blot analysis ( Figure 4B ) showed that the AR protein level in DHT-treated cells increased, compared with solvent-treated cells from relative AR protein (AR/a-tubulin) levels of 1.5 to 2.3. Flutamide was not able to reduce the AR level. In contrast, SKI-606 (10 mM) treatment caused a decrease in AR protein level by about 30% to 40%, probably through the modulation of signaling pathways controlling AR stability. Following treatment of the cells with CC96-EA, CC252-EA, and CC542-C extracts, no decrease in AR protein levels was observed compared with the DHT-treated cells. On the other hand, following CC734-H and CC263-E extract treatment in the presence of DHT, a concentrationdependent decrease in AR protein levels was observed, implying that the inhibition of AR transcriptional activity caused by both extracts (Figure 4A ) was to the result of a reduction in AR protein levels. At present, the mechanism of action of the various C comatus extracts is unclear. However, one can speculate that the CC96-EA, CC252-EA, and CC542-C extracts have similar mechanisms of action and differ from the one exhibited by the CC734-H and CC263-E extracts. CC96-EA, CC252-EA, and CC542-C extracts inhibited AR function by an unknown mechanism, whereas the activity of CC743-H and CC263-E extracts was mediated by downregulation of AR expression.
C comatus Extracts Reduce AR and PSA Expression in LNCaP Cells
PSA is an AR-regulated 34 kDa glycoprotein used as a serum marker for the screening and staging of prostate cancer. 33 LNCaP cells are known to express and secrete PSA. Therefore, we monitored the levels of AR and PSA in LNCaP cells treated with CC734-H and CC263-E extracts using semiquantitative RT-PCR.
Initially, we followed the levels of AR protein in treated LNCaP cell lines. The results presented in Figure 5A show that DHT treatment caused an increase in the steady-state AR protein levels compared with those in solvent-treated cells. In contrast, treatment with flutamide (5 mM) caused a moderate decrease in AR protein levels. Treatments with 50 mg/mL of the CC252-EA, CC734-H, and CC263-E extracts caused a decrease in the AR protein. The CC252-EA extract at a concentration of 50 mg/mL was significantly active in lowering AR protein levels. However, the CC734-H and CC263-E extracts moderately affected AR protein levels. In contrast, treatment with the CC542-C extract at both concentrations, 25 and 50 mg/mL, did not cause a decrease in AR protein levels.
The levels of AR and PSA transcripts were also assessed by semiquantitative RT-PCR. Results shown in Figure 5B demonstrate that the transcript levels of PSA, and to a lesser extent AR, were upregulated in the presence of DHT. The relative levels of PSA/GAPDH were increased from 0.2 to 1 when comparing solvent-treated cells with DHT-treated cells, respectively. However, the relative levels of AR/GAPDH were slightly increased from 0.8 to 1.3 when comparing solvent-treated cells with DHTtreated cells, respectively. The presence of flutamide (5 mM) abrogated the increase in levels of DHT-induced AR and PSA transcripts. The presence of C comatus CC263-E extract caused only a marginal decrease in the levels of AR and PSA transcripts. In contrast, CC252-EA and CC734-H extracts caused a significant reduction in PSA transcripts at higher concentrations. The relative levels of PSA/GAPDH were decreased from 1 to 0.6 and 0.4 when comparing DHT-treated cells with CC252-EA-and CC734-H-treated cells, respectively. However, the relative levels of AR/GAPDH were slightly decreased from 1.3 to 1 and 0.9 when comparing DHT-treated cells with CC252-EA-and CC734-H-treated cells, respectively. C comatus extract CC542-C had no effect on AR and PSA transcript levels. These data provide further evidence that C comatus CC252-EA and CC734-H extracts interfere with AR transcription activity.
Discussion
Prostate cancer is the leading cause of death in older males. Diagnoses of this cancer are often made when the cancer has already advanced to metastasis. Most patients with advanced disease initially respond to androgen ablation therapies. However, after a while, the cancer growth and development becomes independent of androgen, passing into the androgen-independent stage, 34 which has no effective therapy. Therefore, exploration of novel modalities as well as anticancer agents is important. In this regard, many nutritive and nonnutritive phytochemicals with diverse biological activities have shown promising responses in the prevention and/or treatment of prostate cancer. [35] [36] [37] In this study, we investigated the potential anticancer effects of substances presented in a variety of C comatus strains on LNCaP prostate cancer cell lines. Previous results obtained by Zaidman et al 26 showed that E extract prepared from C comatus strain 97 was able to inhibit AR activity in LNCaP cell lines. Our current study was undertaken to identify the most potent C comatus strain and extract. For this purpose, we screened 7 strains of the higher basidiomycetes mushroom C comatus. The biomass of each strain was extracted with 4 different solvents: EA, H, C, and E. The growth medium was also extracted with EA (Table 1) .
We used the MMTV-luciferase stably transfected breast cancer cell line MDA-kb2 to evaluate the effect of C comatus extracts on AR transcriptional activity by monitoring luciferase reporter activity. This system is very suitable for screening AR agonists and antagonists and was previously used by us. 38 In these experiments, 5 nM DHT or 10 nM DEX were used to induce luciferase transcription mediated by nuclear receptors AR and GR, respectively. Out of the 35 extracts screened, 7 exhibited a significant inhibition of AR-mediated reporter activity at a concentration of 50 mg/mL ( Table 2) . Zaidman et al 26 showed that the E extract prepared from C comatus strain 97 inhibited AR transcriptional activity at a concentration of 160 mg/mL by 45%. Consistent with data obtained by Zaidman et al, we found that the CC97-E extract inhibited AR transactivation activity by 40% and was not selected for further analysis. Extracts from the growth medium showed no inhibition of AR transcriptional activity, suggesting that the active compound is not secreted to the medium; therefore, we focused on the biomass extracts. The C extract of C comatus 542 was the only extract that was selective toward AR, as compared with GR. This extract inhibited DHT-induced reporter activity but not DEXinduced reporter activity, suggesting that it may act differently from all other extracts tested, and probably target functions that are unique to AR signaling, as well as the possibility that the C extract of C comatus 542 contains substances that act as a competitor to DHT.
AR regulates many cellular processes in prostate cells, including the growth and survival of androgen-dependent cell lines, such as LNCaP. Thus, active substances from C comatus that interfere mainly with the AR function are expected to affect the proliferation of androgen-dependent and not androgen independent cell lines. The trypan blue dye exclusion membrane integrity assay was used to assess cell viability and to estimate IC 50 values for the 7 selected extracts. It was speculated that mushroom substances capable of interfering with AR activity may also influence the viability of LNCaP cells and have a minimal effect on the androgen-independent cell lines, such as PC-3. Data shown in Table 3 illustrate that C comatus CC542-C, CC734-H, and CC263-E extracts inhibit LNCaP with IC 50 of 23.5, 32, and 30.5 mg/mL, respectively, as compared with PC-3 (122, 68.5, and 99.5 mg/mL, respectively) and MDA-Kb2 cells (125, 125, and 73 mg/mL, respectively), implying a moderate specificity toward LNCaP cells.
Colony formation in semisolid medium is a sensitive test of cell viability and proliferative potential of transformed cells. We monitored the Clonigenicity of LNCaP, DU-145, PC-3, and MDA-Kb2 cell lines in the presence of mushroom extracts. Significant inhibition of Clonigenicity of the LNCaP cells was observed in the presence of the CC542-C, CC734-H, and CC263-E extracts at 50 mg/mL as compared with the solvent-treated cells. In contrast, moderate inhibition was observed in DU-145, PC-3, and MDA-Kb2 cells, providing additional evidence for the selectivity of the C comatus extracts toward the Clonigenicity of the LNCaP cells.
The AR is known to exist as a monomer in the cytoplasm of responsive cells, sequestered in a complex with HSPs. 39, 40 On administration and binding of androgens, the AR changes its conformation, dimerizes, interacts with cofactors, and translocates into the nucleus. In the nucleus, AR, in collaboration with several cofactors, binds to the hormone response element and transcribes AR-responsive genes. 41 Some antiandrogens, such as the nonsteroidal antiandrogen flutamide and its more potent active metabolite 2-hydroxyflutamide, enhance AR turnover by stabilizing the AR-HSP complex, leading to impaired or slower nuclear translocation followed by the inhibition of androgen-dependent DNA and protein synthesis, resulting in tumor cell growth arrest or transient tumor regression. 42, 43 The antiandrogen bicalutamide inhibits the transcription activity of AR by interfering with the binding of coactivators to the AR, resulting in transcriptionally inactive conformation, and not by preventing AR translocation to the nucleus or impairing the AR binding ability to DNA. 44 Flutamide-treated LNCaP cells are therefore unable to transactivate AR-responsive genes, leading to growth inhibition. 45, 46 Levels of AR in the nucleus and cytoplasm were monitored by Western blot in DHT-treated LNCaP cells in the presence and absence of C comatus extracts. The C comatus extracts did not affect the ability of AR to translocate into the nucleus, indicating that this is not the mechanism of action of these extracts. Apparently, the activity of the C comatus extracts is mediated by interfering with AR function in the nucleus. One might argue that C comatus extracts may influence posttranslation modifications such as phosphorylation or acetylation to affect AR functions. Experiments are under way to investigate this possibility.
To evaluate whether the reduction in AR transcriptional activity exhibited by the various C comatus extracts is a result of the reduction in AR levels, MDA-Kb2 cells were treated with 25 or 50 mg/mL of the selected extracts, and AR protein levels were assayed using Western immunoblotting. Treatment of MDA-Kb2 cells with CC96-EA, CC252-EA, and CC542-C extracts exhibited no decrease in AR protein levels. Thus, it may be concluded that reduced AR transactivation function is not a result of the reduced amount of AR protein, but it may be the result of posttranslation modification, thus, supporting our hypothesis. On the other hand, CC734-H and CC263-E extracts brought about a concentration-dependent decrease in AR protein levels, implying that the inhibition in the observed AR transactivation was a consequence of the decrease in AR protein levels.
PSA is the most commonly used biochemical marker for detecting and monitoring prostate cancer. Decreases in PSA levels are associated with a better prostate cancer prognosis. 33 It has been suggested that AR regulates prostate cancer growth and metastasis by modulating the expression of genes involved in prostate tumor growth. 47 Thus, the downregulation of PSA expression may be an important step in the antiproliferative effects of C comatus mushroom extracts in LNCaP cells. The expression levels of AR and PSA in LNCaP cell lines treated with fungal extracts were monitored. A decrease in AR protein levels were observed in cells treated with CC252-EA, CC734-H, and CC263-E extracts and was accompanied by a moderate reduction in AR transcript levels. The levels of PSA transcripts were reduced significantly after treatment with CC252-EA and CC734-H extracts, providing further evidence that the above-mentioned extracts interfere with AR transcription activity. Table 3 summarizes the function of the different C comatus extracts in interfering with AR function. According to Table 3 , CC734-H seems to be the most potent extract, inhibiting AR transcriptional activity by 70% and decreasing AR protein levels in MDA-Kb2 cells. It caused 50% growth inhibition of LNCaP cells with IC 50 of 32 mg/ mL compared with 68 and 125 mg/mL in PC-3 and MDA-Kb2, respectively. CC734-H reduced AR protein levels as well as PSA mRNA levels but was unable to inhibit AR translocation to the nucleus. Similar to bicalutamide, the mechanism might involve inducing an inactive conformation of AR in the nucleus, inhibiting the activity of AR coactivators or altering posttranslation modifications in the AR protein.
Conclusion
The present study demonstrated that H extract prepared from the higher basidiomycetes mushroom C comatus strain 734 was able to interfere with AR function. The organic extract of C comatus was active in inhibiting DHT-and DEX-induced reporter activity mediated by AR-and GR-responsive promoters, respectively. Furthermore, the organic extract of C comatus was effective in inhibiting viability, proliferation, and clonigenicity of LNCaP, the androgen-dependent cell lines. Experiments are under way that are aimed at identifying and elucidating the active constituents as well as their mechanism of action, which will help us in assessing the pharmacological value of C comatus substances as chemotherapeutic agents for prostate cancer.
